Determinant Factors on Differences in Survival for Gastric Cancer Between the United States and Japan Using Nationwide Databases.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 04 2021
Historique:
pubmed: 14 4 2020
medline: 30 6 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

Although the incidence and mortality have decreased, gastric cancer (GC) is still a public health issue globally. An international study reported higher survival in Korea and Japan than other countries, including the United States. We examined the determinant factors of the high survival in Japan compared with the United States. We analysed data on 78,648 cases from the nationwide GC registration project, the Japanese Gastric Cancer Association (JGCA), from 2004-2007 and compared them with 16,722 cases from the Surveillance, Epidemiology, and End Results Program (SEER), a United States population-based cancer registry data from 2004-2010. We estimated 5-year relative survival and applied a multivariate excess hazard model to compare the two countries, considering the effect of number of lymph nodes (LNs) examined. Five-year relative survival in Japan was 81.0%, compared with 45.0% in the United States. After controlling for confounding factors, we still observed significantly higher survival in Japan. Among N2 patients, a higher number of LNs examined showed better survival in both countries. Among N3 patients, the relationship between number of LNs examined and differences in survival between the two countries disappeared. Although the wide differences in GC survival between Japan and United States can be largely explained by differences in the stage at diagnosis, the number of LNs examined may also help to explain the gaps between two countries, which is related to stage migration.

Sections du résumé

BACKGROUND
Although the incidence and mortality have decreased, gastric cancer (GC) is still a public health issue globally. An international study reported higher survival in Korea and Japan than other countries, including the United States. We examined the determinant factors of the high survival in Japan compared with the United States.
METHODS
We analysed data on 78,648 cases from the nationwide GC registration project, the Japanese Gastric Cancer Association (JGCA), from 2004-2007 and compared them with 16,722 cases from the Surveillance, Epidemiology, and End Results Program (SEER), a United States population-based cancer registry data from 2004-2010. We estimated 5-year relative survival and applied a multivariate excess hazard model to compare the two countries, considering the effect of number of lymph nodes (LNs) examined.
RESULTS
Five-year relative survival in Japan was 81.0%, compared with 45.0% in the United States. After controlling for confounding factors, we still observed significantly higher survival in Japan. Among N2 patients, a higher number of LNs examined showed better survival in both countries. Among N3 patients, the relationship between number of LNs examined and differences in survival between the two countries disappeared.
CONCLUSION
Although the wide differences in GC survival between Japan and United States can be largely explained by differences in the stage at diagnosis, the number of LNs examined may also help to explain the gaps between two countries, which is related to stage migration.

Identifiants

pubmed: 32281553
doi: 10.2188/jea.JE20190351
pmc: PMC7940976
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-248

Références

Gastric Cancer. 2013 Jan;16(1):1-27
pubmed: 22729699
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
J Am Coll Surg. 2017 Apr;224(4):546-555
pubmed: 28017807
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
Gastric Cancer. 2018 Jan;21(1):144-154
pubmed: 28417260
Natl Cancer Inst Monogr. 1961 Sep;6:101-21
pubmed: 13889176
Stat Med. 2004 Jan 15;23(1):51-64
pubmed: 14695639
Gastric Cancer. 2011 Oct;14(4):301-16
pubmed: 21894577
Gastric Cancer. 2006;9(2):51-66
pubmed: 16767357
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
Jpn J Clin Oncol. 2008 Apr;38(4):259-67
pubmed: 18344316

Auteurs

Yuri Ito (Y)

Department of Medical Statistics, Research & Development Center, Osaka Medical College.
Cancer Control Center, Osaka International Cancer Institute.

Isao Miyashiro (I)

Cancer Control Center, Osaka International Cancer Institute.

Takashi Ishikawa (T)

Department of Medical Informatics, Niigata University Medical and Dental Hospital.

Kohei Akazawa (K)

Department of Medical Informatics, Niigata University Medical and Dental Hospital.

Keisuke Fukui (K)

Department of Medical Statistics, Research & Development Center, Osaka Medical College.
Cancer Control Center, Osaka International Cancer Institute.

Hitoshi Katai (H)

Department of Gastric Surgery, National Cancer Center Hospital.

Souya Nunobe (S)

Department of Gastroenterological Surgery, Cancer Institute Ariake Hospital.

Ichiro Oda (I)

Endoscopy Division, National Cancer Center Hospital.

Yoh Isobe (Y)

Department of Surgery, National Hospital Organization Tokyo Medical Center.

Shunichi Tsujitani (S)

Department of Gastroenterological Surgery, Tottori University.

Hiroyuki Ono (H)

Endoscopy Division, Shizuoka Cancer Center.

Satoshi Tanabe (S)

Department of Advanced Medicine Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine.

Takeo Fukagawa (T)

Department of Surgery, Teikyo University School of Medicine.

Satoshi Suzuki (S)

Department of Surgery, Kobe University Graduate School of Medicine.

Yoshihiro Kakeji (Y)

Department of Surgery, Kobe University Graduate School of Medicine.

Mitsuru Sasako (M)

Department of Surgery, Hyogo College of Medicine.

Anton Bilchik (A)

Department of Surgical Oncology, The John Wayne Cancer Institute.

Manabu Fujita (M)

Department of Surgical Oncology, The John Wayne Cancer Institute.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH